Professional Documents
Culture Documents
MAN0000662
Corporate Headquarters
5791 Van Allen Way
Carlsbad, CA 92008
T: 1 760 603 7200
F: 1 760 602 6500
E: tech_support@invitrogen.com
For country-specific contact information visit our web site at www.invitrogen.com
User Manual
ii
Table of Contents
About the Kit............................................................................................................. 1
Basic Transformation Procedure............................................................................. 5
Expression Guidelines.............................................................................................. 7
Testing Transformation Efficiency ....................................................................... 11
Technical Support................................................................................................... 12
Purchaser Notification ........................................................................................... 14
iii
iv
Item
BL21(DE3)
BL21(DE3)pLysS
BL21(DE3)pLysE
The table below lists the kits covered by this manual. The
contents of each kit are listed below.
Reactions
Transformation Efficiency
20
Catalog no.
C6000-03
1 10 cfu/g
10
1 10 cfu/g
C6060-10
20
1 108 cfu/g
C6060-03
1 10 cfu/g
20
C6565-03
Shipping/
Storage
Each One Shot kit is shipped on dry ice. Upon receipt, store
at 80C.
Kit Contents
Item
Composition
Amount
SOC Medium
(store at room
temperature or 4C)
6 mL
Chemically
competent cells
pUC19 Control
DNA
10 pg/L in 5 mM Tris-HCl, 50 L
0.5 mM EDTA, pH 8
Continued on next page
pLysS and
pLysE
The BL21(DE3) strain is suitable for use in expressing nontoxic heterologous genes. Recombinant proteins are
generally expressed at higher levels in BL21(DE3) cells than
in BL21(DE3)pLysS or BL21(DE3)pLysE, but basal
expression of heterologous genes is significantly higher in
BL21(DE3) cells than in BL21(DE3)pLysS or BL21(DE3)
pLysE cells as well.
The BL21(DE3)pLysS and BL21(DE3)pLysE strains produce
T7 lysozyme to reduce basal expression of heterologous
genes. These two strains are recommended for use when
expressing toxic genes.
General
Handling
Important
Intended Use
Materials
Supplied by
the User
Before
Starting
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Expression Guidelines
MEND
ION
AT
RECOM
Introduction
Expression of
Non-Toxic
Genes
T7 RNA
Polymerase
and Toxic
Genes
2.
Induction
10
3.
4.
5.
Before Starting
Transformation
Calculation
= # transformants
g plasmid
DNA
11
Technical Support
Web
Resources
Contact Us
Corporate Headquarters:
5791 Van Allen Way
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail: tech_support@invitrogen.com
Japanese Headquarters:
LOOP-X Bldg. 6F
3-9-15, Kaigan
Minato-ku, Tokyo 108-0022
Tel: 81 3 5730 6509
Fax: 81 3 5730 6519
E-mail: jpinfo@invitrogen.com
European Headquarters:
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK
Tel: +44 (0) 141 814 6100
Tech Fax: +44 (0) 141 814 6117
E-mail: eurotech@invitrogen.com
SDS
Certificate of
Analysis
12
13
Purchaser Notification
Introduction
Information
for European
Customers
Limited Use
Label License
No: 30
T7 Expression
System
14
Corporate Headquarters
5791 Van Allen Way
Carlsbad, CA 92008
T: 1 760 603 7200
F: 1 760 602 6500
E: tech_support@invitrogen.com
For country-specific contact information visit our web site at www.invitrogen.com
User Manual